Status:
COMPLETED
The Role of Breastmilk and Serum Exosomes in Neonatal Jaundice Due to ABO Incompatibility
Lead Sponsor:
Kanuni Sultan Suleyman Training and Research Hospital
Conditions:
Neonatal Jaundice From Other Specified Causes
ABO Incompatibility
Eligibility:
All Genders
Up to 28 years
Brief Summary
Neonatal jaundice is a major global health issue that can lead to serious complications and even death if not promptly treated. ABO incompatibility is a common cause of pathological neonatal jaundice,...
Eligibility Criteria
Inclusion
- Newborns who are needed treatment for neonatal jaundice due to ABO incompatibility
- Newborns who are admitted to the study center due to ABO hemolytic disease
- Newborns with ABO incompatibility
- Healthy newborns
- Healthy mothers
Exclusion
- Lack of informed consent
- Congenital abnormalities
- Maternal Liver diseases
- Neonatal liver diseases
- Sepsis
- Neonatal jaundice due to the causes other than ABO incompatibility
- Acute or chronic disease state in newborn
- Maternal acute or chronic disease
- Medication or substance use effecting liver functions
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT06502847
Start Date
July 1 2020
End Date
June 1 2023
Last Update
July 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Health Sciences Istanbul KSS Training and Research Hospital
Istanbul, Kucukcekmece, Turkey (Türkiye), 34303